NKTX Share Price Performance
US$2.07
-3.41 (-62.23%)
Price US$2.07
Share PriceUS$2.07
NKTX Community Narratives
There are no narratives available yet.
Recent NKTX News & Updates
No updates
Nkarta, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.57
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Nkarta, Inc. Competitors
About NKTX
- Founded
- 2015
- Employees
- 109
- CEO
- WebsiteView website
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading